Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
April 16, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 16, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 8, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated ...Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
April 7, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 7, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
March 17, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Mar. 17, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in D ...
March 4, 2026
–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with t ...Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
February 24, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 24, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 18, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 18, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicin ...
February 11, 2026
–Dose-escalating study will evaluate the safety, tolerability and exposure of STK-002 in people with ADOA– –Changes in visual ...Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 4, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 4, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
January 16, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Jan. 16, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from ...
January 11, 2026
— Company now expects to complete enrollment of 150 patients in Q2 2026, with a Phase 3 data readout in mid-2027; Rolling NDA ...Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Jan. 6, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated ...